DOCSLIB.ORG

ABF Metabolic Map 15

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABF Metabolic Map 15 Current ABF target molecule Biological reaction Current ABF beachhead molecule Multiple biological reactions Biomass Polysaccharides Potential beachhead molecule HO This map represents a compilation of metabolic pathways that have been described OH HO HO Glycolic acid HO HO HO O OH O for conversion of biomass-derived polysaccharides to industrial chemicals. OH OOH O O O OH O OH OH OH HO HO OH OH Adapted by permission from Springer Nature Customer Service Centre GmbH: OH OH OH OH OH Ethylene glycol Nature, Nature Catalysis, A comprehensive metabolic map for production of bio- OH OH OH OH HO OH OH L-Arabinose Galactose Glucose D-Xylose D-xylono-1,4-lactone Xylonic acid OH OH OH based chemicals, Lee, S.Y., et al., © 2019 HO OH OH OH OH HO HO OH HO OH 1,2,4-Butanetriol 1,4-Butanediol O OH OH OH Xylitol D-Arabinitol HO HO O O O HO HO NH2 CoA OH S OH Propanol OH Lactaldehyde 4-Hydroxyhexan-3-one HO OH Malonyl-CoA HO Benzyl alcohol Resveratrol Hydroxytyrosol HO - O O O CoA S O O OH -O O O N HO OH OH O O OH H O O OH HO Benzene O 4-phenylbutyrate O Hippurate Acetol Methylglyoxal Ferulic acid p-Coumaroyl-CoA OH O Propanal 1,2-Propanediol HO 4-Hydroxy-2-oxohexanoic acid p-Hydroxystyrene HO NH2 Benzaldehyde HO OH OH OH Dopamine O OH 1,3-Propanediol O O O O O P - OH O HO O O HO HO HO Glycerone HO OH OH O HO HO 6-phenylhexanoate OH cis, cis-Muconic acid HO O OH O Glyceraldehyde OH HO OH OH HO O O O P - Benzoic acid 3-Phosphate Dihydrobenzenediol Caffeic acid p-Coumaric acid O OH HO 1,3-propanediol 3-Hydroxypropanal HO O HO OH HO NH Glycerol O 2 OH O HO NH2 O HO O P OH Dihydroxyacetone phosphate O OH (R)-Mandelate Pentose L-DOPA phosphate HO HO OH OH Tyramine Phenylacetic acid pathway 3-Hydroxypropionic acid Glycerol-3-phosphate HO NH2 HO O OH HO O O OH O O HO HO OH HO HO OH HO L-Tyrosine O HO O O OH OH Catechol O Phenol OH Phenylglyoxylate Acrylic acid 3-Hydroxypropionic acid D-Glyceraldehyde D-Glycerate O HO O Phenyl acetaldehyde Phenylethanol O O O HO HO NH2 OH HO O OH O O O HO OH O- OH O O O H2N 2-Pyrone- 4-Hydroxyphenyllactic Toluene O O β-ketoadipic acid OH O O O HO OH OH O O 4,6-dicarboxylic acid acid Tyrosol OH OH O O P OH P (S)-Mandelate OH H2N H N HO O P OH NH2 OH 2 O OH NH2 OH O OH OH OH OH D-Phenylglycine O O L-Phenylglycine NH2 O Glycine 3-Phospho- 4,5-Dioxopentanoate 5-Aminolevulinate L-Serine O-Phospho-L-serine O 3-Phosphooxypyruvate D-glycerate OH HO OH HO HO O O OH H2N OH O O O O O O O OH H2N OH HO HO OH HO 2-Butanol NH2 OH Protocatechuic acid Vanillin 4-Hydroxyphenylacetic acid Prephenic acid Phenylpyruvate L-Phenylalanine Phenethylamine Ethanolamine HO O HO HO P O O O OH HO O O OH O OH O O O O OH 4-methyl-1-pentanol OH * * HO D-Erythrose 4-phosphate HO OH OH O O S CoA HO OH trans-Cinnamic acid HO O O 4-Hydroxymandelic acid Phenyllactic acid Poly(3HB-co-PhLA) Propanol Propionyl-CoA Butanone Meso-2,3-Butanediol 3-Methyl-1-butanol 2-Ketoisoheptanoate Isocaproate HO OH HO CoA HO HO O O S O OH OH O O OH HO O P HO HO HO OH O O HO O OH HO O O O OH OH O O HO HO HO HO 3-Deoxy-D-arabino- O HO 4-Hydroxybenzoic acid 4-Hydroxybenzoate-CoA Styrene HO O OH Shikimic acid Chorismate O heptulosonate-7-phosphate 3-Dehydroshikimate O HO O O OH OH O P OH (S,S)-2,3-Butanediol (R,R)-2,3-Butanediol 2-Ketoisocaproate Isovalerate 3-Hydroxyisovalerate HO NH2 HO S CoA OH O HO HO O O O 4-Aminobenzoic acid NH2 Acrylyl-CoA Propionic acid O Phosphoenolpyruvate HO OH OH O HO NH2 HO HO Danshensu O Isobutanol 4-aminophenylacetic acid OH 4-aminophenylpyruvate H2N - O O O O H NH Isochorismate HO O 2 O OH OH O O Anthranilate O NH 2 O HO - NH2 HO O NH HO 4-aminophenylacetaldehyde O NH2 OH 2 O O O O O O (S)-Acetoin Acetolactate 2-Ketoisovalerate HO NH NH2 (R)-acetoin L-Valine HO 2 N S CoA OH N N H NH H 2 4-aminophenylalanine OH OH O L-Tryptophan Serotonin 5-methoxytryptamine H2N OH O Acrylic acid HO 4-aminophenylethanol Lactyl-CoA NH Lactic acid O Aniline L-Leuc2ine HO OH H H2N N O NH2 NH2 O H O Isopentane Isobutyrate N 4-aminocinnamic acid 4-aminophenylethylamine O O O O OH CO2 + H2 S CoA HO O Melatonin HO OH Formic acid O O O O O n 4-Methylpentanoic acid Isobutyryl-CoA O 4-methyl-1-pentanol Pyruvate Polylactic acid HO S CoA S CoA HO O HO S CoA Ethanol )-3-Hydroxybutyryl-CoA Crotonoyl-CoA Butyryl-CoA 1-Butanol O (S HO O O O Isobutyl acetate HO HO O OH Isobutanol HO O OH O O R S ACP O Acetaldehyde O Adipic acid R S ACP Isoamyl acetate HO 2-Hydroxyisobutyrate Acyl-ACP OH O O OH O O OH O Enoyl-ACP R OH O O Citramalate Hexanoic acid Pentane S ACP S CoA OH Fatty alcohol HO HO S CoA (C5 or longer) Acetoacetyl-CoA O HO O (R)-3-Hydroxybutyryl-CoA (R)-3-Hydroxybutyrate R OEt Acetyl-ACP 3-Methyl-1-butanol Acetate O OH OH FAEE Butyrate HO OH O O HO Octanoic acid O O 1,3-Butanediol R O O O OH O acetone Isopropanol R OMe Fatty acids HO S ACP HO S CoA FAME OH Malonyl-CoA Malonyl-ACP S CoA HO Propane O HO R O O HO Prenol Myrcene Farnesene Acetyl-CoA Geranylgeraniol Alkene OH OH O OH R S ACP OH R Mevalonic acid Geraniol Limonene Farnesol R S ACP Alkane β-Keto acyl-ACP O O Santalene (C7 or longer) O HO β-Hydroxy acyl-ACP O H O HO OH HO O P O OHO O O O P OH Pentadecaheptaene P P 3-Hydroxypropionic acid 3-Pentanone 2-Butanone O O OH O O O O P O O H O P H H P P HO O O Isoprene O OHO OH HO Isopentenenyl Geranyl Farnesyl Geranylgeranyl O O O diphosphate diphosphate diphosphate NH diphosphate 2 S Kaurene HO O HO NH2 O O OH NH2 O O OH Ethylene 1-Aminocyclopropane-1- NH2 OH O O carboxylic acid O O L-Methionine HO OH HO O Malonic acid OH Oxaloacetate HO OH H H OH O β-Alanine OH OH NH2 O HO HO H2N Citrate OH H2N NH2 L-Aspartate Isoprenol Pinene Sabinene Artemisinic acid β-Carotene O Propanol Propionic acid L-Homoalanine 1,3-Diaminopropane OH OH O OH Cineole Bisabolene O HO O NH2 NH2 OH OH OH OH O HO HO HO NH2 1,2,4-Butanetriol HO O O OH HO O H O OH O O HO HO H2N N O NH2 HO O HO - O O O OH NH NH O O Itaconic acid cis-Aconitate O NH OH O O H N N Astaxanthin L-Isoleucine 2-Ketobutyric acid L-Threonine Homoserine OH 2 L-Homocarnosine 4-Guanidinobutanoate Aspartate OH HO semialdehyde HO Malate HO OH O 1-Butanol O O O OH O OH HO HO HO O OH 2,4-Dihydroxybutyrate O 2-Methyl-1-butanol P HO NH2 OH O NH2 O H2N NH2 HO OH O HO O O O 3-Methyl-1-pentanol D-Glucosamine 6- L-2-Aminoadipate O OH O O HO O H2N phosphate OH OH N γ-Aminobutyric acid 4-Aminobutyraldehyde OH Glyoxylate HO Isocitrate H O OH O H2N γ-Aminobutyric acid Butyrolactam H2N H2N O HO O (E)-2-Methyl-2-pentenoic acid NH2 O Ethylene OH O HO H2N O H N 4-Hydroxyvaleric acid NH2 2 O OH NH Tiglic acid OH O Oxalic acid H N OH HN O 2 O OH O L-β-Lysine HN Mesaconate O OH O HO O O L-Lysine L-ɑ-Aminocaprolactam HO O O NH2 O OH O O S CoA L-Glutamine Indigoidine Propionyl-CoA O OH HO OH 2-Methylpentanoic acid HO HO O HO NH2 O O O 2-Methylbutyric acid OH Fumarate O HO O- O OH NH2 Levulinic acid H2N O HO N HO NH H2N HO 6-Hydroxyhexanoic acid ɑ-Ketoglutarate 2 O O O H H2N NH2 NH2 Putrescine HO O O 2,3-Dihydroxybutyrate L-Glutamate N-Acetyl-L-ornithine Cadaverine L-Ornithine O β-Hydroxy-ɣ- OH H2N O O Heptanoic acid butyrolactone O O Pentanoic acid NH2 OH O O HN HO S CoA Propionic acid HO O NH2 5-Aminopentanamide S CoA H O O HO O HO H N N OH O OH H 2 Methylmalonyl-CoA OH O NH2 NH2 O O HO O NH2 N OH OH O Succinyl-CoA O O N-Carbamoyl putrescine ɑ-Ketoglutarate semialdehyde 6-Aminocaproic acid Citrulline Butane Glycolic acid OH Succinic acid O O OH L-Proline Lactic acid O N O - O H2N O HO L-1-Pyrroline- O O OH O OH OH O 5-carboxylate NH2 HN 3-Pentanone 5-Methyl-3-hexanone O HO HO HO H2N HN O O O N N HN Adipic acid OH OH H H O O HO OH O N O NH NH OH HN 2 2 Valerolactam 5-Aminovaleric acid OH OH O OH HO O Glycolaldehyde Arginosuccinate Agmatine 2-Dehydro-3-deoxy- 2-Dehydro-3-deoxy- Caprolactam O N Succinate semialdehyde OH O L-arabinonate D-arabinonate H O D-Proline L-Hydroxyproline O n m NH2 O O O OH O O Poly(lactic-co-glycolic acid) HO OH O OH O O O O N O N H2N O NH2 O OH HO OH OH HO O H O O OH OH OH H N HN - OH H2N N OH 2 OH HO OH HO OH Ethylene glycol O HO HO HO OH OH O NH Glutarate semialdehyde O S CoA OH NH O Suberic acid Glutaric acid D-Xylonate L-Arabinoate 1-Pyrroline- NH O 4-Hydroxybutyryl-CoA 4-Hydroxybutyric acid 2-carboxylate 5-Aminovaleric acid Proclavaminate L-Arginine Gamma-butyrolactone Feruloylagmatine HO HO O O OH HO O OH O OH O O O O OH OH NH2 HO OH O HN HO O OH NH H OH H2N N H2N N OH O HO OH H2N N OH OH OH HO O Sebacic acid 7-Hydroxyheptanoic acid Pimelic acid OH OH NH2 O HO O NH O D-Xylose L-Arabinose Octopine 2-Oxoarginine Nopaline 1,4-Butanediol 4-Hydroxybutyraldehyde.
Load more

Recommended publications
  • WO 2013/180584 Al 5 December 2013 (05.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/180584 Al 5 December 2013 (05.12.2013) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12N 1/21 (2006.01) C12N 15/74 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C12N 15/52 (2006.01) C12P 5/02 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C12N 15/63 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/NZ20 13/000095 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 4 June 2013 (04.06.2013) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/654,412 1 June 2012 (01 .06.2012) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: LANZATECH NEW ZEALAND LIMITED MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, [NZ/NZ]; 24 Balfour Road, Parnell, Auckland, 1052 (NZ).
    [Show full text]
  • S-Abscisic Acid
    CLH REPORT FOR[S-(Z,E)]-5-(1-HYDROXY-2,6,6-TRIMETHYL-4-OXOCYCLOHEX-2-EN- 1-YL)-3-METHYLPENTA-2,4-DIENOIC ACID; S-ABSCISIC ACID CLH report Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2 International Chemical Identification: [S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2- en-1-yl)-3-methylpenta-2,4-dienoic acid; S-abscisic acid EC Number: 244-319-5 CAS Number: 21293-29-8 Index Number: - Contact details for dossier submitter: Bureau REACH National Institute for Public Health and the Environment (RIVM) The Netherlands [email protected] Version number: 1 Date: August 2018 Note on confidential information Please be aware that this report is intended to be made publicly available. Therefore it should not contain any confidential information. Such information should be provided in a separate confidential Annex to this report, clearly marked as such. [04.01-MF-003.01] CLH REPORT FOR[S-(Z,E)]-5-(1-HYDROXY-2,6,6-TRIMETHYL-4-OXOCYCLOHEX-2-EN- 1-YL)-3-METHYLPENTA-2,4-DIENOIC ACID; S-ABSCISIC ACID CONTENTS 1 IDENTITY OF THE SUBSTANCE........................................................................................................................1 1.1 NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE...............................................................................................1 1.2 COMPOSITION OF THE SUBSTANCE..........................................................................................................................1 2 PROPOSED HARMONISED
    [Show full text]
  • Relationship to Atherosclerosis
    AN ABSTRACT OF THE THESIS OF Marilyn L. Walsh for the degree of Doctor of Philosophy in Biochemistry and Biophysics presented on May 3..2001. Title: Protocols. Pathways. Peptides and Redacted for Privacy Wilbert Gamble The vascular system transports components essential to the survival of the individual and acts as a bamer to substances that may injure the organism. Atherosclerosis is a dynamic, lesion producing disease of the arterial system that compromises the functioning of the organ by occlusive and thrombogenic processes. This investigation was undertaken to elucidate some of the normal biochemical processes related to the development of atherosclerosis. A significant part of the investigation was directed toward developing and combining methods and protocols to obtain the data in a concerted manner. A postmitochondnal supernatant of bovine aorta, usingmevalonate-2-14C as the substrate, was employed in the investigation. Methods included paper, thin layer, and silica gel chromatography; gel filtration, high performance liquid chromatography (HPLC), and mass spectrometry. This current research demonstrated direct incorporation of mevalonate-2- 14Cinto the trans-methyiglutaconic shunt intermediates. The aorta also contains alcohol dehydrogenase activity, which converts dimethylallyl alcohol and isopentenol to dimethylacrylic acid, a constituent of the trans-methylgiutaconate Small, radioactive peptides, named Nketewa as a group, were biosynthesized using mevalonate-2-'4C as the substrate. They were shown to pass through a 1000 D membrane. Acid hydrolysis and dabsyl-HPLC analysis defined the composition of the Nketewa peptides. One such peptide, Nketewa 1, had a molecular weight of 1038 and a sequence of his-gly-val-cys-phe-ala-ser-met (HGVCFASM), with afarnesyl group linked via thioether linkage to the cysteine residue.
    [Show full text]
  • Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
    Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders.
    [Show full text]
  • Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A
    University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 10-19-2010 Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A. Crooks University of Kentucky, [email protected] Aimee K. Bence David R. Worthen Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Crooks, Peter A.; Bence, Aimee K.; and Worthen, David R., "Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders" (2010). Pharmaceutical Sciences Faculty Patents. 47. https://uknowledge.uky.edu/ps_patents/47 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007816407B2 (12) United States Patent (10) Patent N0.: US 7,816,407 B2 Crooks et al. (45) Date of Patent: Oct. 19, 2010 (54) AGMATINE AND AGMATINE ANALOGS IN The Merck Index, Merck Research Laboratories Division of Merck & THE TREATMENT OF EPILEPSY, SEIZURE, Co., Inc. 1996, p. 35. AND ELECTROCONVULSIVE DISORDERS James O. McNamara, “Drugs Effective in Therapy of the Epilepsies”, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, (75) Inventors: Peter A. Crooks, Lexington, KY (US); Ninth Edition, Chapter 20, pp. 461-486, 1996. Aimee K. Bence, Lexington, KY (US); I. Tayfun Uzbay et al., “Effects of agmatine on ethanol Withdrawal David R.
    [Show full text]
  • Figure S1. Heat Map of R (Pearson's Correlation Coefficient)
    Figure S1. Heat map of r (Pearson’s correlation coefficient) value among different samples including replicates. The color represented the r value. Figure S2. Distributions of accumulation profiles of lipids, nucleotides, and vitamins detected by widely-targeted UPLC-MC during four fruit developmental stages. The colors indicate the proportional content of each identified metabolites as determined by the average peak response area with R scale normalization. PS1, 2, 3, and 4 represents fruit samples collected at 27, 84, 125, 165 Days After Anthesis (DAA), respectively. Three independent replicates were performed for each stages. Figure S3. Differential metabolites of PS2 vs PS1 group in flavonoid biosynthesis pathway. Figure S4. Differential metabolites of PS2 vs PS1 group in phenylpropanoid biosynthesis pathway. Figure S5. Differential metabolites of PS3 vs PS2 group in flavonoid biosynthesis pathway. Figure S6. Differential metabolites of PS3 vs PS2 group in phenylpropanoid biosynthesis pathway. Figure S7. Differential metabolites of PS4 vs PS3 group in biosynthesis of phenylpropanoids pathway. Figure S8. Differential metabolites of PS2 vs PS1 group in flavonoid biosynthesis pathway and phenylpropanoid biosynthesis pathway combined with RNA-seq results. Table S1. A total of 462 detected metabolites in this study and their peak response areas along the developmental stages of apple fruit. mix0 mix0 mix0 Index Compounds Class PS1a PS1b PS1c PS2a PS2b PS2c PS3a PS3b PS3c PS4a PS4b PS4c ID 1 2 3 Alcohols and 5.25E 7.57E 5.27E 4.24E 5.20E
    [Show full text]
  • Plasma Mevalonate As a Measure of Cholesterol Synthesis in Man
    Plasma mevalonate as a measure of cholesterol synthesis in man. T S Parker, … , J Chen, P J De Schepper J Clin Invest. 1984;74(3):795-804. https://doi.org/10.1172/JCI111495. Research Article Measurement of mevalonic acid (MVA) concentrations in plasma or 24-h urine samples is shown to be useful in studies of the regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and cholesterol synthesis. Plasma MVA concentrations, measured either at 7-9 a.m. after an overnight fast, or throughout the 24-h cycle, were compared with cholesterol synthesis rates that were measured by the sterol balance method: plasma MVA concentrations were directly related to the rate of whole body cholesterol synthesis (r = 0.972; p less than 0.001; n = 18) over a tenfold range of cholesterol synthesis rates. Moreover, hourly examination of MVA concentrations throughout the day demonstrated that interventions such as fasting or cholesterol feeding cause suppression of the postmidnight diurnal rise in plasma MVA concentrations, with little change in the base-line of the rhythm. Thus, the daily rise and fall of plasma MVA appears to reflect changes in tissues and organs, such as the liver and intestine, that are known to be most sensitive to regulation by fasting or by dietary cholesterol. The hypothesis that short-term regulation of HMG-CoA reductase in tissues is quickly reflected by corresponding variations in plasma MVA was tested by using a specific inhibitor of HMG-CoA reductase, mevinolin, to block MVA synthesis. Mevinolin caused a dose-dependent lowering of plasma MVA after a single dose; and in patients who […] Find the latest version: https://jci.me/111495/pdf Plasma Mevalonate as a Measure of Cholesterol Synthesis in Man Thomas S.
    [Show full text]
  • Vitamin D Receptor Promotes Healthy Microbial Metabolites
    www.nature.com/scientificreports OPEN Vitamin D receptor promotes healthy microbial metabolites and microbiome Ishita Chatterjee1, Rong Lu1, Yongguo Zhang1, Jilei Zhang1, Yang Dai 2, Yinglin Xia1 ✉ & Jun Sun 1 ✉ Microbiota derived metabolites act as chemical messengers that elicit a profound impact on host physiology. Vitamin D receptor (VDR) is a key genetic factor for shaping the host microbiome. However, it remains unclear how microbial metabolites are altered in the absence of VDR. We investigated metabolites from mice with tissue-specifc deletion of VDR in intestinal epithelial cells or myeloid cells. Conditional VDR deletion severely changed metabolites specifcally produced from carbohydrate, protein, lipid, and bile acid metabolism. Eighty-four out of 765 biochemicals were signifcantly altered due to the Vdr status, and 530 signifcant changes were due to the high-fat diet intervention. The impact of diet was more prominent due to loss of VDR as indicated by the diferences in metabolites generated from energy expenditure, tri-carboxylic acid cycle, tocopherol, polyamine metabolism, and bile acids. The efect of HFD was more pronounced in female mice after VDR deletion. Interestingly, the expression levels of farnesoid X receptor in liver and intestine were signifcantly increased after intestinal epithelial VDR deletion and were further increased by the high-fat diet. Our study highlights the gender diferences, tissue specifcity, and potential gut-liver-microbiome axis mediated by VDR that might trigger downstream metabolic disorders. Metabolites are the language between microbiome and host1. To understand how host factors modulate the microbiome and consequently alter molecular and physiological processes, we need to understand the metabo- lome — the collection of interacting metabolites from the microbiome and host.
    [Show full text]
  • Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action
    molecules Review Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action Matthew E. Bergman 1 , Benjamin Davis 1 and Michael A. Phillips 1,2,* 1 Department of Cellular and Systems Biology, University of Toronto, Toronto, ON M5S 3G5, Canada; [email protected] (M.E.B.); [email protected] (B.D.) 2 Department of Biology, University of Toronto–Mississauga, Mississauga, ON L5L 1C6, Canada * Correspondence: [email protected]; Tel.: +1-905-569-4848 Academic Editors: Ewa Swiezewska, Liliana Surmacz and Bernhard Loll Received: 3 October 2019; Accepted: 30 October 2019; Published: 1 November 2019 Abstract: Specialized plant terpenoids have found fortuitous uses in medicine due to their evolutionary and biochemical selection for biological activity in animals. However, these highly functionalized natural products are produced through complex biosynthetic pathways for which we have a complete understanding in only a few cases. Here we review some of the most effective and promising plant terpenoids that are currently used in medicine and medical research and provide updates on their biosynthesis, natural occurrence, and mechanism of action in the body. This includes pharmacologically useful plastidic terpenoids such as p-menthane monoterpenoids, cannabinoids, paclitaxel (taxol®), and ingenol mebutate which are derived from the 2-C-methyl-d-erythritol-4-phosphate (MEP) pathway, as well as cytosolic terpenoids such as thapsigargin and artemisinin produced through the mevalonate (MVA) pathway. We further provide a review of the MEP and MVA precursor pathways which supply the carbon skeletons for the downstream transformations yielding these medically significant natural products. Keywords: isoprenoids; plant natural products; terpenoid biosynthesis; medicinal plants; terpene synthases; cytochrome P450s 1.
    [Show full text]
  • Inhibition of Hepatic Cholesterol Synthesis
    Proc. Nati Acad. Sci. USA Vol. 79, pp. 4873-4877, August 1982 Biochemistry Inhibition of hepatic cholesterol synthesis- in mice by sterols with shortened and stereochemically varied side chains [feedback regulation/3-hydroxy-3-methylglutaryl-coenzyme A reductase/mevalonic acid/(E)- and (Z)-17(20)-dehydrocholesterol/ pregn-5-en-3.&ol] KATHERINE A. ERICKSON* AND WILLIAM R. NESt Department ofBiological Sciences, Drexel University, Philadelphia, Pennsylvania 19104 Communicated by E. H. Ahrens, Jr., May 5, 1982 ABSTRACT Micewere fedcholesterol orvarious other sterols chain found in cholesterol. The literature provided no guidance for 26 hr, after which the amount ofhepatic cholesterol synthesis on the effect that this changewould have. The only steroids with was measured in a cell-free system. The following sterols were as shortened side chains previously examined (hormones and bile effective as cholesterol itself in, depressing the conversion of ace- acids) have had oxygen atoms on or in place of the side chain tate into sterol: pregn-5.en-3.&ol, which lacks an isohexyl group (10-12). Polar groups, ofcourse, would be expected to have a on C-20; (E)-17(2G)-dehydrocholesterol, in which the isohexyl marked effect in their own-right. In addition, many ofthe com- group is fixed to the right; (E)-20(22)-dehydrocholesterol, in which pounds-e.g., bile acids and testosterone-also had- changes C-23 is oriented away from the nucleus; and 20-epicholesterol. in the In order to make an exact comparison with cho- Moreover, when the isohexyl group was fixed to the left in (Z)- nucleus. 17(20)-dehydrocholesterol, this dietary sterol, identified in the lesterol we used the 3,(3hydroxy-A5-sterols (androst-5-en-3/-ol liver, causednotonly a depression in the conversion ofacetate into and pregn-5-en-3(-ol), which had no other polar groups and sterols but also-a depression in the conversion of both mevalonate zeroandtwocarbon atoms on C-17, respectively.
    [Show full text]
  • European Patent Office
    (19) & (11) EP 2 380 989 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 C12Q 1/26 (2006.01) C12N 1/20 (2006.01) C12N 9/02 (2006.01) (21) Application number: 10731334.8 (86) International application number: (22) Date of filing: 19.01.2010 PCT/JP2010/050565 (87) International publication number: WO 2010/082665 (22.07.2010 Gazette 2010/29) (84) Designated Contracting States: (72) Inventor: MATSUOKA, Takeshi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tokyo 101-8101 (JP) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Forstmeyer, Dietmar et al BOETERS & LIECK (30) Priority: 19.01.2009 JP 2009009177 Oberanger 32 80331 München (DE) (71) Applicant: Asahi Kasei Pharma Corporation Tokyo 101-8101 (JP) (54) METHOD AND REAGENT FOR DETERMINING MEVALONIC ACID, 3- HYDROXYMETHYLGLUTARYL-COENZYME A AND COENZYME A (57) The present invention provides a method for taryl coenzyme A in the presence of a hydrogen acceptor measuring the concentration of an analyte in a test so- X, a hydrogen donor Y, and coenzyme A; and (q) a step lution wherein the analyte is mevalonic acid and/or 3- of measuring an amount of: a reduced hydrogen acceptor hydroxymethylglutaryl coenzyme A, comprising the fol- X that is produced; or an oxidized hydrogen donor Y that lowing steps (p) and (q): (p) a step of allowing an enzyme is produced; or a hydrogen acceptor X that is decreased; that catalyzes a reaction represented by Reaction For- or a hydrogen donor Y that is decreased, wherein the mula 1 and an enzyme that catalyzes a reaction repre- hydrogen donor Y and the reduced hydrogen acceptor sented by Reaction Formula 2 to act on a test solution X are not the same.
    [Show full text]
  • Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.12.988600; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Uncovering new drug properties in target-based drug-drug similarity networks Lucret¸iaUdrescu1, Paul Bogdan2, Aimee´ Chis¸ 3, Ioan Ovidiu Sˆırbu3,6, Alexandru Topˆırceanu4, Renata-Maria Varut¸˘ 5, and Mihai Udrescu4,6,* 1”Victor Babes¸” University of Medicine and Pharmacy Timis¸oara, Department of Drug Analysis, Timis¸oara 300041, Romania 2University of Southern California, Ming Hsieh Department of Electrical Engineering, Los Angeles, CA 90089-2563, USA 3”Victor Babes¸” University of Medicine and Pharmacy Timis¸oara, Department of Biochemistry, Timis¸oara 300041, Romania 4University Politehnica of Timis¸oara, Department of Computer and Information Technology, Timis¸oara 300223, Romania 5University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Craiova 200349, Romania 6Timis¸oara Institute of Complex Systems, Timis¸oara 300044, Romania *[email protected] ABSTRACT Despite recent advances in bioinformatics, systems biology, and machine learning, the accurate prediction of drug properties remains an open problem. Indeed, because the biological environment is a complex system, the traditional approach – based on knowledge about the chemical structures – cannot fully explain the nature of interactions between drugs and biological targets. Consequently, in this paper, we propose an unsupervised machine learning approach that uses the information we know about drug-target interactions to infer drug properties.
    [Show full text]